Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will
View HTML
Toggle Summary Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the pricing of its
View HTML
Toggle Summary Nabriva Therapeutics Announces Proposed Public Offering
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a
View HTML
Toggle Summary Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support -A ccelerates milestone payments to Nabriva , including fourth quarter 2020   payment of $1 million DUBLIN, Ireland , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a
View HTML
Toggle Summary Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
DUBLIN, Ireland , Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
DUBLIN, Ireland , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
-Relaunch of Xenleta ® and Sivextro ® commenced in late September-   - Type A Meeting with FDA for Contepo™ held on October 30 th - -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
View HTML
Toggle Summary Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
DUBLIN, Ireland , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial
View HTML
Toggle Summary Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)
-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes -- -- Pooled analysis of data by age group from pivotal LEAP 1 and LEAP 2 Phase 3
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com